Revenue (Tables)

12 Months Ended

Dec. 31, 2020

Disaggregation of Revenue [Abstract]

Disaggregation of Revenue [Table Text Block]

The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):

	Year Ended December 31,
	2020						2019						2018
Businesses	U.S.		OUS		Total		U.S.		OUS		Total		U.S.		OUS		Total
Endoscopy	$	1,000	$	780	$	1,780	$	1,080	$	814	$	1,894	$	980	$	781	$	1,762
Urology and Pelvic Health	918		368		1,286		1,005		408		1,413		864		381		1,245
Cardiac Rhythm Management	992		712		1,704		1,135		804		1,939		1,159		792		1,951
Electrophysiology	118		169		287		148		180		329		150		161		311
Neuromodulation	610		151		761		695		178		873		624		155		779
Interventional Cardiology	981		1,317		2,299		1,293		1,522		2,816		1,154		1,436		2,590
Peripheral Interventions	888		689		1,577		741		651		1,392		608		579		1,187
Specialty Pharmaceuticals	193		27		219		70		11		81		n/a		n/a		n/a
Net Sales	$	5,701	$	4,212	$	9,913	$	6,167	$	4,569	$	10,735	$	5,538	$	4,286	$	9,823

	Year Ended December 31,
Geographic Regions	2020		2019		2018
U.S.	$	5,508	$	6,097	$	5,538
EMEA (Europe, Middle East and Africa)	2,097		2,264		2,176
APAC (Asia-Pacific)	1,781		1,898		1,727
LACA (Latin America and Canada)	307		395		383
Medical Devices	9,694		10,654		9,823
U.S.	193		70		n/a
International	27		11		n/a
Specialty Pharmaceuticals	219		81		n/a
Net Sales	$	9,913	$	10,735	$	9,823
Emerging Markets(1)	$	1,093	$	1,252	$	1,097

(1)    We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets which is currently comprised of the following countries: Argentina, Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Thailand, Turkey and Vietnam.